{"organizations": [], "uuid": "4666d5eeb214f80cc4dc80abb8b672bd3fbe9e3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zogenix-announces-receipt-of-fda-b/brief-zogenix-announces-receipt-of-fda-breakthrough-therapy-designation-for-zx008-idUSASB0C478", "country": "US", "domain_rank": 408, "title": "BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T15:05:00.000+02:00", "replies_count": 0, "uuid": "4666d5eeb214f80cc4dc80abb8b672bd3fbe9e3a"}, "author": "", "url": "https://www.reuters.com/article/brief-zogenix-announces-receipt-of-fda-b/brief-zogenix-announces-receipt-of-fda-breakthrough-therapy-designation-for-zx008-idUSASB0C478", "ord_in_thread": 0, "title": "BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "zogenix inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 6, 2018 / 1:05 PM / Updated 14 minutes ago BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008 Reuters Staff \nFeb 6 (Reuters) - Zogenix Inc: \n* ZOGENIX ANNOUNCES RECEIPT OF FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IN DRAVET SYNDROME \n* ZOGENIX INC - FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IS BASED ON RESULTS FROM STUDY 1 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-06T15:05:00.000+02:00", "crawled": "2018-02-06T15:27:12.046+02:00", "highlightTitle": ""}